A multicenter phase II study of eribulin monotherapy in patients with BRAF V600E mutant metastatic colorectal cancer
收藏NIAID Data Ecosystem2026-03-10 收录
官方服务：
资源简介：
Interventions: Eribulin is administered intravenously at a dose of 1.4mg/m^2/day on Days 1 and 8, repeated every 21 days. Primary outcome(s): Confirmed objective response rate(ORR) by investigators’ assessment Study Design: Single arm Non-randomized
创建时间：
2018-03-15
